Therapies / Cellular / Genes / Gene / Gene Therapy / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Alnylam Pharmaceuticals / Avigen / Biogen / BioMarin Pharmaceutical / Biotech / clinical trials / emicizumab / FDA / FEIBA / fitusiran / Genentech / Glenn Pierce / Hemlibra / hemophilia / hemophilia A / hemophilia B / Hemophilia Federation of America / Kimberly Haugstad / Life Sciences / Mark Skinner / Roche / Shire / Spark Therapeutics / Valoctocogene roxaparvovec / World Federation of Hemophilia

Gene Therapy Advances, But Hemophilia is no Easy Target

Posted on: Dec 13, 2017   |   Posted by: Biotech Mag

Gene Therapy Advances, But Hemophilia is no Easy Target

Mark Skinner, the former longtime president of the World Federation of Hemophilia, has had the blood disease on his mind his entire life. He doesn't have a choice. Skinner, 57...

Continue reading ...



Other Posts from Biotech Mag